Does radiofrequency ablation add to chemotherapy for unresectable liver metastases?

12Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

In patients with unresectable colorectal liver metastases (CRLM), radiofrequency ablation (RFA) might be a good alternative, whenever possible. In contrast to systemic therapy, the aim of RFA is to achieve complete local tumor control in an attempt to provide long-term survival. In this article we discuss the available evidence regarding the treatment of patients with unresectable CRLM, focusing on RFA in conjunction with modern systemic therapies. We observed that the available evidence in the existing literature is limited, and often consists of level 2 and 3 evidence, thereby hampering any firm conclusions. Nonetheless, RFA seems superior to chemotherapy alone in patients with liver-only disease amenable for RFA. However, the combination of RFA and chemotherapy has been demonstrated to be feasible and safe, lending support to the concept of RFA followed by chemotherapy, in order to reduce local recurrence rates and prolong survival. © The Author(s) 2012.

Cite

CITATION STYLE

APA

Govaert, K. M., Van Kessel, C. S., Lolkema, M., Ruers, T. J. M., & Rinkes, I. H. M. B. (2012). Does radiofrequency ablation add to chemotherapy for unresectable liver metastases? Current Colorectal Cancer Reports, 8(2), 130–137. https://doi.org/10.1007/s11888-012-0122-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free